Monitor the effectiveness of the S-4 registration statement and shareholder votes for the merger, as well as the IND submission for CLD-423 Phase 2b UC trial expected in Q4 2026. The Phase 1a data and new license are positive for Caldera's pipeline but do not change the near-term deal timeline.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+5- T+0 · Nov 5 $0.5600entry
- T+1 · 11d ago 0.00%α −0.31% · $0.5600
- T+5 · 5d ago 0.00%α −3.29% · $0.5600
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Caldera Therapeutics, the private biotech merging with Synlogic (SYBX), announced positive Phase 1a data for its lead bispecific antibody CLD-423 and an exclusive worldwide license for a preclinical IL-17 x TL1A bispecific program from Qyuns Therapeutics. The data support planned Phase 2 trials in ulcerative colitis and Crohn's disease starting in early 2027, and the license expands Caldera's pipeline. The filing is a routine M&A communication that adds no new financial terms or changes to the pending all-stock merger and concurrent $278 million private placement.
Key Financial Metrics
Key Facts
- Caldera reported Phase 1a data for CLD-423 (IL-23p19 x TL1A bispecific) showing favorable tolerability, no dose-limiting toxicities, prolonged half-life (>40 days IV), and sustained TL1A target engagement.
- Phase 2b UC trial and Phase 2a CD trial planned to start in early 2027, with data readouts expected between late 2027 and end of 2028.
- Caldera entered an exclusive worldwide license with Qyuns Therapeutics for a preclinical IL-17 x TL1A bispecific antibody program.
- The all-stock merger with Synlogic and concurrent private placement of ~$278 million remain on track for early 2027 closing.
- No changes to deal terms, timeline, or financial structure were disclosed in this filing.
Financial Impact
No new financial figures; the concurrent private placement remains at approximately $278 million in gross proceeds.
Risk Factors
- Phase 2 clinical trials may fail to replicate Phase 1a safety/efficacy results.
- Merger and private placement remain subject to shareholder approvals and customary closing conditions.
- Immunogenicity data showed anti-drug antibodies in 8 of 42 subjects, though titers were low and no safety findings were attributed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-448753 |
| Document: 0001193125-26-448753-index-headers.html | 0001193125-26-448753 |
| Document: 0001193125-26-448753-index.html | 0001193125-26-448753 |
| Document: 0001193125-26-448753.txt | 0001193125-26-448753 |
Track record
5 reports on SYBX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 425 Neutral 4/10 Viewing Entry $0.5600 Now $1.10 +96.43% settles Feb 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $0.5600 Now $1.10 +96.43% settles Jan 29
- Jul 29, 202615w ago 425 / 8-K Bearish 7/10 Entry $1.12 to $1.08 Now $1.10 +1.79% ▲ +3.57% +9.82% vs SPY
- May 18, 202626w ago 25-NSE Bearish 7/10 Entry $0.6600 to $1.21 Now $1.10 −66.67% ▼ −82.58% −77.72% vs SPY
- Apr 30, 202628w ago 10-K/A Neutral 2/10 Entry $0.6050 to $0.7150 Now $1.10 +81.82% ▲ +18.18% +15.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers